Literature DB >> 26641631

Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study.

Signe Vedel-Krogh1,2,3, Sune F Nielsen1,2,3, Peter Lange2,4,5, Jørgen Vestbo6, Børge G Nordestgaard1,2,3.   

Abstract

RATIONALE: Whether high blood eosinophils are associated with chronic obstructive pulmonary disease (COPD) exacerbations among individuals with COPD in the general population is largely unknown.
OBJECTIVES: To test the hypothesis that high blood eosinophils predict COPD exacerbations.
METHODS: Among 81,668 individuals in the Copenhagen General Population Study, we examined 7,225 with COPD based on spirometry. We recorded blood eosinophils at baseline and future COPD exacerbations longitudinally, defined as moderate (short-course treatment with systemic corticosteroids) or severe (hospitalization). We also assessed exacerbation risk in a subgroup of 203 individuals with clinical COPD, defined as participants with a smoking history of at least 10 pack-years, FEV1 less than 70% of predicted value, and at least one moderate or severe exacerbation in the year before baseline.
MEASUREMENTS AND MAIN RESULTS: During a median of 3.3 years of follow-up (range, 0.03-8.1), 1,439 severe and 2,864 moderate COPD exacerbations were recorded. Among all participants with COPD, blood eosinophils above versus below 0.34 × 10(9) cells per liter had multivariable-adjusted incidence rate ratios of 1.76 (95% confidence interval, 1.56-1.99) for severe exacerbations and 1.15 (1.05-1.27) for moderate exacerbations. Corresponding values in those with clinical COPD were 3.21 (2.49-4.14) and 1.69 (1.40-2.04). In contrast, using a cutpoint of 2% for blood eosinophils, the risk of exacerbations was increased for severe exacerbations only among individuals with clinical COPD and not in individuals in the broader population.
CONCLUSIONS: Among individuals with COPD in the general population, increased blood eosinophil levels above 0.34 × 10(9) cells per liter were associated with a 1.76-fold increased risk of severe exacerbations.

Entities:  

Keywords:  epidemiology; granulocytes; lung disease; prospective study

Mesh:

Year:  2016        PMID: 26641631     DOI: 10.1164/rccm.201509-1869OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  117 in total

1.  Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease.

Authors:  Jeong H Yun; Andrew Lamb; Robert Chase; Dave Singh; Margaret M Parker; Aabida Saferali; Jørgen Vestbo; Ruth Tal-Singer; Peter J Castaldi; Edwin K Silverman; Craig P Hersh
Journal:  J Allergy Clin Immunol       Date:  2018-04-28       Impact factor: 10.793

Review 2.  Evolving Concepts in Chronic Obstructive Pulmonary Disease Blood-Based Biomarkers.

Authors:  Mario Cazzola; Ermanno Puxeddu; Josuel Ora; Paola Rogliani
Journal:  Mol Diagn Ther       Date:  2019-10       Impact factor: 4.074

Review 3.  An update on the use of inhaled therapy in COPD.

Authors:  Oliver Price; Chandra Sarkar; Shruthi Konda
Journal:  Clin Med (Lond)       Date:  2018-10       Impact factor: 2.659

Review 4.  The Reemergence of the Asthma-COPD Overlap Syndrome: Characterizing a Syndrome in the Precision Medicine Era.

Authors:  Stephanie A Christenson
Journal:  Curr Allergy Asthma Rep       Date:  2016-11       Impact factor: 4.806

Review 5.  Machine Learning Characterization of COPD Subtypes: Insights From the COPDGene Study.

Authors:  Peter J Castaldi; Adel Boueiz; Jeong Yun; Raul San Jose Estepar; James C Ross; George Washko; Michael H Cho; Craig P Hersh; Gregory L Kinney; Kendra A Young; Elizabeth A Regan; David A Lynch; Gerald J Criner; Jennifer G Dy; Stephen I Rennard; Richard Casaburi; Barry J Make; James Crapo; Edwin K Silverman; John E Hokanson
Journal:  Chest       Date:  2019-12-28       Impact factor: 9.410

6.  Blood biomarkers as predictors of long-term mortality in COPD.

Authors:  Angelico Mendy; Erick Forno; Theophile Niyonsenga; Janvier Gasana
Journal:  Clin Respir J       Date:  2018-01-05       Impact factor: 2.570

7.  Anti-IL-5 therapies for chronic obstructive pulmonary disease.

Authors:  Tim Donovan; Stephen J Milan; Ran Wang; Emma Banchoff; Patrick Bradley; Iain Crossingham
Journal:  Cochrane Database Syst Rev       Date:  2020-12-08

8.  Eosinophils and eosinophil-associated diseases: An update.

Authors:  Jeremy A O'Sullivan; Bruce S Bochner
Journal:  J Allergy Clin Immunol       Date:  2017-10-16       Impact factor: 10.793

Review 9.  Targeting Chronic Obstructive Pulmonary Disease Phenotypes, Endotypes, and Biomarkers.

Authors:  Suresh Garudadri; Prescott G Woodruff
Journal:  Ann Am Thorac Soc       Date:  2018-12

10.  Biomarkers Predictive of Exacerbations in the SPIROMICS and COPDGene Cohorts.

Authors:  Jason D Keene; Sean Jacobson; Katerina Kechris; Gregory L Kinney; Marilyn G Foreman; Claire M Doerschuk; Barry J Make; Jeffrey L Curtis; Stephen I Rennard; R Graham Barr; Eugene R Bleecker; Richard E Kanner; Eric C Kleerup; Nadia N Hansel; Prescott G Woodruff; MeiLan K Han; Robert Paine; Fernando J Martinez; Russell P Bowler; Wanda K O'Neal
Journal:  Am J Respir Crit Care Med       Date:  2017-02-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.